Fierce Medtech Names Enable Injections a "Fierce 15" Company of 2023

enFuse is designed for compatibility with small molecule and biologic drug formulations across a wide range of viscosities and volumes (5-25mL for a single device, and up to 100mL with multiple devices). The recognition from Fierce follows the recent U.S. FDA approval and launch of the first combination product utilizing the enFuse technology. Enable is currently working with a number of pharma partners to advance several ongoing clinical studies evaluating their therapies in combination with enFuse wearable technology for a broad range of diseases where infusion treatment is typically required.

enFuse is designed for compatibility with small molecule and biologic drug formulations across a wide range of viscosities and volumes (5-25mL for a single device, and up to 100mL with multiple devices). The recognition from Fierce follows the recent U.S. FDA approval and launch of the first combination product utilizing the enFuse technology. Enable is currently working with a number of pharma partners to advance several ongoing clinical studies evaluating their therapies in combination with enFuse wearable technology for a broad range of diseases where infusion treatment is typically required.

About Enable Injections
Cincinnati-based Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable's body-worn enFuse^® delivers high-volume pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. Approved in the United States in combination with a specific drug, more information: https://enableinjections.com/our-products.

Logo - https://mma.prnewswire.com/media/962405/Enable_Injections_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fierce-medtech-names-enable-injections-a-fierce-15-company-of-2023-302080162.html